Studies have confirmed that monotherapy of pembrolizumab offers sustained anti-tumor activity in patients with early and advanced PD-L1-positive TNBC (with a combined positive score [CPS] of ≥ 1) [54–56]. Here, CD274 is linked to neoplasm.